Evidence map›Paper›PMID 33983837›Full record

ReviewCirculation research2021

Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure.

Joyce N Njoroge, John R Teerlink

2 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Circulation research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 121 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed, 12 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06414759 phase4unknown statusnot on this mapstarted 2024, after this paper: background citation

Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload

TypeinterventionalSponsorCairo UniversityRan2024 to 2025Enrolled110ConditionsAcute Decompensated Heart Failure, Volume Overload, EdemaArmsAcetazolamide, Metolazone, IV Loop Diuretics
NCT06921603 narecruitingnot on this mapstarted 2025, after this paper: background citation

Point-of-Care Ultrasound-Guided Diuresis for Acute Decompensated Heart Failure to Reduce 30-Day Readmissions and Acute Kidney Injury

TypeinterventionalSponsorUniversity of PittsburghRan2025 to 2026Enrolled588ConditionsHeart Decompensation, Acute, Acute Kidney InjuriesArmsFurosemide (Standard Diuretic) Treatment, POCUS-Assessed Diuretic Management
3 · Its place in the literature

Who cites it

121 citing papers in PubMed, 12 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Common Variants onCirculation. Heart failure · 2023
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. An integrated overview of acute heart failure: a narrative review of pathophysiological mechanisms and contributing factors.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026
    Review
  16. PaOCJC open · 2026
    Article
  17. Observational
  18. Article
  19. HLM Staging and Treatment Benefit of SGLT2i Across Heart Failure Severity.Journal of cardiovascular development and disease · 2026
    Article
  20. Article

61 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Joyce N NjorogeDivision of Cardiology, School of Medicine, University of California San Francisco (J.N.N., J.R.T.), San Francisco, CA.
John R TeerlinkDivision of Cardiology, School of Medicine, University of California San Francisco (J.N.N., J.R.T.), San Francisco, CA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute decompensated heart failure (ADHF) is one of the leading admission diagnoses worldwide, yet it is an entity with incompletely understood pathophysiology and limited therapeutic options. Patients admitted for ADHF have high in-hospital morbidity and mortality, as well as frequent rehospitalizations and subsequent cardiovascular death. This devastating clinical course is partly due to suboptimal medical management of ADHF with persistent congestion upon hospital discharge and inadequate predischarge initiation of life-saving guideline-directed therapies. While new drugs for the treatment of chronic HF continue to be approved, there has been no new therapy approved for ADHF in decades. This review will focus on the current limited understanding of ADHF pathophysiology, possible therapeutic targets, and current limitations in expanding available therapies in light of the unmet need among these high-risk patients.

Indexed as

Acute DiseaseBody FluidsCardio-Renal SyndromeCardiotoxinsComorbidityHeart FailureHospitalizationHumansInflammation MediatorsMyocardial ContractionNatriuretic Peptide, BrainPatient DischargePatient ReadmissionRenin-Angiotensin SystemSymptom AssessmentVascular ResistanceCardiotoxinsInflammation MediatorsNatriuretic Peptide, BrainVasodilator Agentsdiagnosisheart failurehospitalizationmorbiditymortalitytherapeutics

Identifiers

PMID33983837
PMCPMC8126502

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.